Vince Bertucci, MD, FRCPC: Bertucci MedSpa
8333 Weston Road, Suite 100
Woodbridge, ON L4L 8E2
Phone: (905) 850-4415
Hours:
Monday: 8 a.m.–5 p.m.
Tuesday: 9 a.m.–5 p.m.
Wednesday – Thursday: 8 a.m.–5 p.m.
Friday: 8 a.m.–4 p.m.
Degrees & Certifications
1992 – 1995
Dermatology, University of Toronto, FRCPC, DABD
1989 – 1992
Internal Medicine, University of Toronto, FRCPC
1985 – 1989
Doctor of Medicine (M.D.), Faculty of Medicine, University of Toronto.
1983 – 1985
Physiology Programme, Faculty of Arts and Science, University of Toronto.
1978 – 1983
Dante Alighieri Academy High School, Toronto, Ontario Secondary School Honour Graduation Diploma
Post-Graduate Training
07/1995 – 06/1996
Fellowship, Dermatologic Surgery, University of Toronto
07/1994 – 06/1995
Chief Resident, Dermatology, University of Toronto
07/1992 – 06/1994
Resident, Dermatology, University of Toronto
07/1989 – 06/1992
Resident, Internal Medicine, University of Toronto
Employment
2000 – Present
Founder & Medical Director, Bertucci MedSpa, Woodbridge, Ontario, Canada
2001 – 2003
Medical Consultant, Ventana Clinical Research Corporation, Toronto, Ontario, Canada
1996 – 2000
Dermatologist, Group Practice, Toronto, Ontario, Canada
1997 – 1998
Consultant Dermatologist, Meaford General Hospital, Meaford, Ontario, Canada
Academic Appointments & Activities
2010 – Present
Co-Director, Dermatologic Laser Surgery and Aesthetic Dermatology Fellowship, University of Toronto, Canada
1997 – Present
Instructor, Division of Dermatology, Department of Medicine, University of Toronto, Canada
1996 – Present
Consultant Dermatologist, Women’s College Hospital, University of Toronto, Canada
2011 – 2016
Examiner, Royal College of Physicians and Surgeons of Canada.
1997 – 2008
Co-Director, Undergraduate Dermatology, University of Toronto, Canada
Research / Clinical Trials Activity
2023 – Present
Principal Investigator: An international, multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars. Sponsor: AbbVie.
2023 – Present
Principal Investigator: A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of Restylane Lyft Lidocaine for jawline definition. Device Study. Sponsor: Galderma.
2022 – Present
Principal Investigator: An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation. Device Study. Phase 3. Sponsor: AbbVie.
2022 – Present
Principal Investigator: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety Principal Investigator: A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies. Device Study. Sponsor: Galderma.
2022-2023
Principal Investigator: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence. Phase 3. Sponsor: AbbVie.
2021-2023
Principal Investigator: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse Shape + with Lidocaine versus Juvederm Voluma with Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment. Phase 4. Sponsor: Prollenium Medical Technologies Inc.
2020-2021
Principal Investigator: A Prospective, Single blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers. Phase 4. Sponsor: Revance Therapeutics Inc.
2020-2022
Principal Investigator: A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region. Phase 3. Sponsor: Q-Med AB / Galderma.
2020-2021
Principal Investigator: A Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane. Phase 4. Sponsor: Q-Med AB / Galderma.
2020 – 2021
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (REDADY-3). Phase 3. Sponsor: Galderma.
2019 – 2021
Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines with or without Concurrent Treatment of Lateral Canthal Lines. Phase 3. Sponsor: Allergan Inc.
2019 – 2020
Principal Investigator: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence. Sponsor: Allergan Inc.
2019 – 2020
Principal Investigator: Post Marketing study to evaluate lip enhancement, naturalness and partner/subject satisfaction after treatment with Restylane Kysse. Phase 4. Sponsor: Galderma.
2018 – 2020
Principal Investigator: Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment. Phase 4. Sponsor: Allergan Inc.
2019 – 2020
Principal Investigator: A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections. Phase 2a. Sponsor: Revance Therapeutics Inc.
2017 – 2018
Principal Investigator: An Open Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN LABEL SAFETY). Phase 3. Sponsor: Revance Therapeutics Inc.
2016 – 2017
Principal Investigator: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2). Phase 3. Sponsor: Revance Therapeutics Inc.
2016
Principal Investigator: A Multi-Center Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine. Phase 4. Sponsor: Galderma Laboratories, L.P.
2016
Principal Investigator: BOTOX® Treatment of Masseter Muscle Hypertrophy. Phase 3. Sponsor: Allergan Inc.
2015 – 2016
Principal Investigator: Evaluation of the Merz Jawline Grading Scale Following Radiesse (+)® Correction of Subcutaneous Volume Loss and Contour Deficits of the Jawline – a Canadian Pilot Study. Sponsor: Merz North America, Inc.
2015
Principal Investigator: A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines. Phase 2. Sponsor: Revance Therapeutics Inc.
2013 – 2014
Principal Investigator: OnabotulinumtoxinA in the Treatment of Forehead Lines. Sponsor: Allergan Inc.
2013 – 2014
Principal Investigator: A Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled Study of Subject Satisfaction of BOTOX® Cosmetic Treatment in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc.
2012 – 2013
Principal Investigator: Evaluation of Pain with the Use Of Radiesse® with Lidocaine for the Treatment of Nasolabial Folds. Sponsor: Merz Aesthetics, Inc.
2012 – 2013
Principal Investigator: Multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area. Sponsor: Kythera Biopharmaceuticals, Inc.
2011 – 2012
Principal Investigator: Efficacy and Safety comparison of adapalene 0.1% / benzoyl peroxide 2.5% gel associated with 200 mg doxycycline capsules versus vehicle gel associated with isotretinoin capsules in the treatment of severe acne. Sponsor: Galderma Research & Development.
2011 – 2012
Principal Investigator: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc.
2011
Principal Investigator: Evaluation of Pain with the Use Of Radiesse® with Lidocaine for the Treatment of Nasolabial Folds. Sponsor: Merz Aesthetics, Inc.
2010 – 2011
Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). Sponsor: Allergan Inc.
2010 – 2011
Principal Investigator: A Randomized, Single-Blind Study Evaluating the Safety and Effectiveness of the LipoSonix™ System when Treating Adipose Tissue at Single and Multiple Focal Depths with the Same Energy Level after One or Two Treatments. Sponsor: Medicis Technologies Corporation.
2010 – 2011
Principal Investigator: An Open Label, Multicenter Study of the Safety and Efficacy of Perlane-L™ Injectable Gel in the Correction of Midface Volume Loss and/or Midface Contour Deficiency. Sponsor: Medicis Global Services Corporation.
2003
Subinvestigator: Canadian Phase 4 Open-Label Multi-Centre Study of Botox for Treatment of Patients with Axillary Hyperhidrosis.
2001 – 2002
Subinvestigator: An Open-Label, Multi-Centre Study of the Efficacy of Various Treatment Schedules of VAS972 in Patients with Moderate to Severe Psoriasis. Sponsor: Vasogen Inc.
2001 – 2002
Subinvestigator: A 12-week, randomised, double-blind, placebo-controlled, multi-centre, parallel-group, dose-finding study to determine the dose response, safety and tolerability of three doses (10, 20, 30 mg b.i.d.) of SDZ ASM 981 tablets in subjects with atopic dermatitis. Phase IIb. Sponsor: Novartis Pharma AG.
January 12, 2002
How to be a Good Clinical Trials Investigator, Women’s College Hospital, Division of Dermatology, University of Toronto, Canada
June 2, 2001
Clinical Trials Workshop, Dermatology Nurses Association, Toronto, Canada
Editorial Activity
2014
Editorial: Innovations in Aesthetic Dermatology 2014, CDA eBulletin, December 2014 Issue
2012
Editorial: The Evolving Aesthetic Medicine Landscape, The Chronicle of Cosmetic Medicine + Surgery, Summer 2012 Issue
2012
Guest Editor, The Chronicle of Cosmetic Medicine + Surgery, Summer 2012 Issue
2011 – Present
Editorial Board, The Chronicle of Cosmetic Medicine + Surgery
2010 – Present
Contributing Editor, Dermatologic Surgery
2009 – Present
Contributing Editor, Journal of Cutaneous Medicine & Surgery
October 2009
Guest Editor, Canadian Dermatology Association Bulletin, Dermatologic Surgery Issue
June 2008
Guest Editor, Canadian Dermatology Association Bulletin, Dermatologic Surgery Issue
Honours & Awards
2022
President’s Award, American Society for Dermatologic Surgery.
2022
Award of Merit, Canadian Dermatology Association.
2021
President’s Award, American Society for Dermatologic Surgery.
2020
President’s Award, American Society for Dermatologic Surgery.
2009
Canadian Dermatology Association, Young Dermatologists’ Volunteer Award.
2008
University of Toronto, Division of Dermatology, Undergraduate Dermatology Education Award.
2002
Nominated for Dermatology Teacher of the Year Award, Dermatology Residency Program, University of Toronto.
1996
F.M. Hill Research Award, Women’s College Hospital, Toronto.
1987-1988
Honours Standing, Faculty of Medicine, University of Toronto
1985
National Science and Engineering Research Council of Canada Scholarship
1983-1985
Faculty Scholar, University of Toronto, Canada.
1983-1985
Admission Scholarship, St. Michael’s College, University of Toronto, Canada.
Professional Activities and Affiliations
2023-2024
Immediate Past President, American Society for Dermatologic Surgery.
2023-2024
Chair, Executive Director Search Task Force, American Society for Dermatologic Surgery.
2022-2023
President, American Society for Dermatologic Surgery.
2022-2023
Chair, Strategic Planning Task Force, American Society for Dermatologic Surgery.
Sep 9-10, 2023
Co-Director, Advanced Injection Techniques Course, American Society for Dermatology Surgery. New York, NY.
Jul 4, 2023
Co-Director, Fillers and Threads Course. World Congress of Dermatology, Singapore.
Mar 20, 2023
Director, Soft Tissue Fillers: Video Instruction and Live Panel Discussion. American Academy of Dermatology Annual Meeting, New Orleans, LA.
Oct 7, 2022
Director, Facial Assessment and Fillers, American Society for Dermatologic Surgery Annual Meeting, Denver, CO.
Sep 10-11, 2022
Director, 360-Degree Injection Techniques and Strategy Course, American Society for Dermatologic Surgery, Chicago, IL.
Mar 26, 2022
Director, Soft Tissue Fillers: Video Instruction & Panel Discussion Course. American Academy of Dermatology Annual Meeting, Boston, MA.
2021-2022
President-Elect, American Society for Dermatologic Surgery.
2021-2024
Member, Awards Work Group, American Society for Dermatologic Surgery.
Nov 19, 2021
Director, Hands-On Cosmetics Course, American Director, Facial Assessment and Fillers, American Society for Dermatologic Surgery Annual Meeting [Virtual].
Nov 6-7, 2021
Director, Hands-On Cosmetics Course, American Academy of Dermatology, Chicago, IL.
Sep 11-12, 2021
Director, Advanced Injection Techniques Course, American Society for Dermatologic Surgery, New York City, NY
Mar 17, 2021
Cardiopulmonary Resuscitation (CPR) Certification, Canadian Red Cross
2020 – 2021
Vice President, American Society for Dermatologic Surgery
2020
Member, Taskforce on Guidance Regarding SARS-CoV-2 mRNA Vaccine Side Effects in Dermal Filler Patients, American Society for Dermatologic Surgery.
2021 – 2023
Chair, Membership Committee, American Academy of Dermatology.
Oct 11, 2020
Director, Facial Assessment and Fillers Course,
ASDS Annual Meeting. [Virtual].
Sep 11-13, 2020
Director, Advanced Anatomy and Injection Techniques Course, American Society for Dermatologic Surgery.
2020 – 2021
Member, Taskforce on Guidance for Cosmetic Dermatology Practices During COVID-19, American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery.
2019 – 2021
Deputy Chair, Membership Committee, American Academy of Dermatology.
2019 – 2020 and 2013 – 2014
Mentor, Future Leaders Network, American Society for Dermatologic Surgery.
2017 – 2020
Member, Board of Directors, American Society for Dermatologic Surgery.
2019
Chair, Task Force on Educating Clinical Staff at the Annual Meeting, American Society for Dermatologic Surgery.
2019– and 2011–15
Executive Committee, Toronto Dermatological Society
2017 – 2019
Chair, Leadership Development Work Group, American Society for Dermatologic Surgery.
Nov 23-24, 2019
Director, Advanced Injection Techniques: Maximize Safety and Minimize Complications Course, American Society for Dermatologic Surgery, New York City, NY.
October 24, 2019
Director, Soft Tissue Fillers: Advanced Video Instruction with Panel Discussion, American Society for Dermatologic Surgery Annual Meeting, Chicago, IL
March 4, 2019
Director, Soft Tissue Fillers: Video Instruction and Live Panel Discussion. American Academy of Dermatology Annual Meeting, Washington, DC.
October 13, 2018
Director, Facial Finesse Part 2: Gender and Ethnic Analysis and Treatment. American Society for Dermatologic Surgery Annual Meeting, Phoenix, AZ.